This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

ISARIC/WHO Clinical Characterisation Protocol for Severe Emerging Infections [COVID-19] [UPH]

  • Research type

    Research Study

  • Full title

    Novel Coronavirus Observational Study

  • IRAS ID

    126600

  • Contact name

    Calum Semple

  • Contact email

    M.G.Semple@liverpool.ac.uk

  • Sponsor organisation

    University of Oxford

  • ISRCTN Number

    ISRCTN 66726260

  • Clinicaltrials.gov Identifier

    CPMS 14152, ; ,

  • Research summary

    New infectious agents, such as the SARS coronavirus, new strains of influenza, and HIV, continually appear and require new investigations to understand how the disease works and how it interacts with the person infected. There is an urgent need to conduct coordinated clinical research relating to the COVID-19 outbreak to learn more about the virus and to provide evidence to help decide treatments and to ensure an effective public health response. This study will provide rapid, coordinated clinical investigation of patients with confirmed COVID-19 infection. It will look at how the virus reproduces and is excreted by the body, how the body responds to infection and treatment over time and how the immune system responds. The study has been designed to ensure that as much data as possible is collected and shared rapidly in a format that can be easily added together, tabulated and analysed across many different settings globally. It is designed to be flexible to ensure the best acceptance by health care organisations. [COVID-19 amendment – 24/02/2020]

  • REC name

    South Central - Oxford C Research Ethics Committee

  • REC reference

    13/SC/0149

  • Date of REC Opinion

    2 Mar 2013

  • REC opinion

    Favourable Opinion